

# Contents

- 1 Metabolism of Lipoproteins and Their Role in the Pathogenesis of Atherosclerosis  
*Daniel Steinberg*
- 25 Morphological Changes in Atherosclerosis and the Effects of Hyperlipidemia on the Artery Wall  
*Neville Woolf*
- 49 Dyslipidemia as a Risk Factor for Cardiovascular Disease and Untimely Death: The Framingham Study  
*Joseph Stokes III*
- 59 Clinical Trials of Cholesterol Lowering  
*Basil M. Rifkind*
- 71 Strategies for the Prevention of Coronary Heart Disease: The European Document  
*Mario Mancini and Claudio Cortese*
- 75 New Guidelines for Lowering Blood Cholesterol and Coronary Risk  
*DeWitt S. Goodman*
- 85 The LDL Receptor Concept: Clinical and Therapeutic Implications  
*Michael S. Brown and Joseph L. Goldstein*
- 95 Hypercholesterolemia: A Public Health Problem  
*Michael G. Marmot*
- 109 Pharmacologic Control of Plasma Cholesterol: Mechanisms of Action of Hypocholesterolemic Agents  
*James Shepherd and Christopher J. Packard*
- 123 HMG-CoA Reductase Inhibitors—The Development  
*Alfred W. Alberts*
- 133 Clinical Trials of Lovastatin and Simvastatin Versus Cholestyramine  
*Donald B. Hunninghake*



- 139 Comparative Study of Lovastatin Versus Probucol in the Treatment of Hypercholesterolemia  
*Jean Davignon, Marianne Xhignesse, H el ene Mailloux, A. Christine Nestruck, Suzanne Lussier-Cacan, Ghislaine Roederer, and Pascal Pfister*
- 153 Effect of Simvastatin on Lipids, Apolipoproteins, and Lipoprotein Particles in Primary Hypercholesterolemia  
*J. M. Bard, G. Luc, P. Douste-Blazy, P. Drouin, O. Ziegler, B. Jacotot, J. Emmerich, J. L. De Gennes, and J. C. Fruchart*
- 161 Long-Term Experience with HMG-CoA Reductase Inhibitors in the Therapy of Hypercholesterolemia  
*D. Roger Illingworth, Sandra P. Bacon, and Kathleen K. Larsen*
- 189 Lovastatin and Simvastatin: An Overview  
*J. Findlay Walker and Jonathan A. Tobert*
- 195 Subject Index